335 related articles for article (PubMed ID: 24518085)
1. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.
Pelosi G; Rindi G; Travis WD; Papotti M
J Thorac Oncol; 2014 Mar; 9(3):273-84. PubMed ID: 24518085
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
4. What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?
Pelosi G; Fabbri A; Cossa M; Sonzogni A; Valeri B; Righi L; Papotti M
Semin Diagn Pathol; 2015 Nov; 32(6):469-79. PubMed ID: 26561395
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.
Fabbri A; Cossa M; Sonzogni A; Papotti M; Righi L; Gatti G; Maisonneuve P; Valeri B; Pastorino U; Pelosi G
Virchows Arch; 2017 Feb; 470(2):153-164. PubMed ID: 28054150
[TBL] [Abstract][Full Text] [Related]
7. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
[TBL] [Abstract][Full Text] [Related]
8. Utility of the quantitative Ki-67 proliferation index and CD56 together in the cytologic diagnosis of small cell lung carcinoma and other lung neuroendocrine tumors.
Zheng G; Ettinger DS; Maleki Z
Acta Cytol; 2013; 57(3):281-90. PubMed ID: 23635388
[TBL] [Abstract][Full Text] [Related]
9. [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
Langfort R; Rudziński P; Burakowska B
Pneumonol Alergol Pol; 2010; 78(1):33-46. PubMed ID: 20162517
[TBL] [Abstract][Full Text] [Related]
10. Automated quantification of Ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors.
Wang HY; Li ZW; Sun W; Yang X; Zhou LX; Huang XZ; Jia L; Lin DM
Chin Med J (Engl); 2019 Mar; 132(5):551-561. PubMed ID: 30807354
[TBL] [Abstract][Full Text] [Related]
11. Advances in neuroendocrine lung tumors.
Travis WD
Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
[TBL] [Abstract][Full Text] [Related]
12. Biology and novel therapeutics for neuroendocrine tumors of the lung.
Jafri N; Salgia R
J Biol Regul Homeost Agents; 2004; 18(3-4):275-90. PubMed ID: 15786694
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine neoplasms of the lung: a prognostic spectrum.
Asamura H; Kameya T; Matsuno Y; Noguchi M; Tada H; Ishikawa Y; Yokose T; Jiang SX; Inoue T; Nakagawa K; Tajima K; Nagai K
J Clin Oncol; 2006 Jan; 24(1):70-6. PubMed ID: 16382115
[TBL] [Abstract][Full Text] [Related]
14. [Pulmonary neuroendocrine neoplasms].
Sayeg Y; Sayeg M; Baum RP; Kulkarni HR; Presselt N; Mäder I; Kunze A; Sänger J; Hörsch D; Bonnet R
Pneumologie; 2014 Jul; 68(7):456-77. PubMed ID: 25006841
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors.
Galván JA; Astudillo A; Vallina A; Crespo G; Folgueras MV; González MV
BMC Cancer; 2014 Nov; 14():855. PubMed ID: 25413006
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of neuroendocrine lung tumors.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2014 Sep; 50(9):392-6. PubMed ID: 24685201
[TBL] [Abstract][Full Text] [Related]
17. Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.
Pelosi G; Papotti M; Rindi G; Scarpa A
Endocr Pathol; 2014 Jun; 25(2):151-64. PubMed ID: 24771462
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.
Kaemmerer D; Specht E; Sänger J; Wirtz RM; Sayeg M; Schulz S; Lupp A
J Clin Endocrinol Metab; 2015 Mar; 100(3):831-40. PubMed ID: 25494861
[TBL] [Abstract][Full Text] [Related]
19. [Neuroendocrine tumors of the lung].
Takei H; Asamura H
Nihon Rinsho; 2004 May; 62(5):877-82. PubMed ID: 15148812
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors.
Orozco-Morales M; Avilés-Salas A; Hernández-Pedro N; Catalán R; Cruz-Rico G; Colín-González AL; Dosal-Mancilla E; Barrios-Bernal P; Arrieta O
J Immunol Res; 2021; 2021():6632249. PubMed ID: 34195295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
